Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG

Tuberculosis

Volumn 93, Issue 2, 2013, Pages 143-149

  Tameris, Michele ^a   McShane, Helen ^b   McClain, J Bruce ^c   Landry, Bernard ^c   Lockhart, Stephen ^d   Luabeya, Angelique K K ^a   Geldenhuys, Hennie ^a   Shea, Jacqui ^d   Hussey, Gregory ^a   Van Der Merwe, Linda ^a   De Kock, Marwou ^a   Scriba, Thomas ^a   Walker, Robert ^c   Hanekom, Willem ^a   Hatherill, Mark ^a   Mahomed, Hassan ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AERAS   (United States)

^d Oxford Emergent Tuberculosis Consortium ^*  (United Kingdom)

Author keywords

BCG; Implementation; Lessons learnt; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; SOUTH AFRICA; TUBERCULOSIS;

BCG VACCINE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; INFANT; PATIENT SELECTION; RESEARCH DESIGN; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 84875210302     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2013.01.003     Document Type: Article

References (41)

1. World Health Organisation Guidance for national tuberculosis programmes on the management of tuberculosis in children 2006
2. B.B. Trunz, P. Fine, and C. Dye Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness Lancet 367 2006 1173 1180
3. Department of Health South Africa demographic and health survey 1998 1999 Department of Health and Medical Research Council Pretoria, South Africa
4. World Health Organisation Global tuberculosis control 2011
5. L.C. Rodrigues, V.K. Diwan, and J.G. Wheeler Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis Int J Epidemiol 22 1993 1154 1158
6. P.E.M. Fine, I.A.M. Carneiro, J.B. Milstein, and C.J. Clements Issues relating to the use of BCG in immunization programs 1999 WHO Geneva
7. Stop TB Working Group on TB vaccines TB vaccine pipeline 2011 [accessed 14.08.12] http://wwwstoptborg/wg/new-vaccines/assets/documents/ TB%20Vaccine%20Pipeline%202011-FINALpdf
8. H. McShane, S. Behboudi, N. Goonetilleke, R. Brookes, and A.V. Hill Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A Infect Immun 70 2002 1623 1626
9. T.J. Scriba, M. Tameris, E. Smit, L. van der Merwe, and E.J. Hughes A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults Am J Respir Crit Care Med 185 2012 769 778
10. T.J. Scriba, M. Tameris, N. Mansoor, E. Smit, and L. van der Merwe Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants J Infect Dis 203 2011 1832 1843
11. T.J. Scriba, M. Tameris, N. Mansoor, E. Smit, and L. van der Merwe Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells Eur J Immunol 40 2010 279 290
12. T. Hawkridge, T.J. Scriba, S. Gelderbloem, E. Smit, and M. Tameris Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa J Infect Dis 198 2008 544 552
13. C.R. Sander, A.A. Pathan, N.E. Beveridge, I. Poulton, and A. Minassian Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals Am J Respir Crit Care Med 179 2009 724 733
14. R.H. Brookes, P.C. Hill, P.K. Owiafe, H.B. Ibanga, and D.J. Jeffries Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa PLoS One 3 2008 e2921
15. N.E. Beveridge, D.A. Price, J.P. Casazza, A.A. Pathan, and C.R. Sander Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations Eur J Immunol 37 2007 3089 3100
16. A.M. Minassian, R. Rowland, N.E. Beveridge, I.D. Poulton, and I. Satti A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults BMJ Open 1 2011 e000223
17. A.A. Pathan, A.M. Minassian, C.R. Sander, R. Rowland, and D.W. Porter Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults Vaccine 30 2012 5616 5624
18. A.A. Odutola, O.A. Owolabi, P.K. Owiafe, H. McShane, and M.O. Ota A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants Vaccine 30 2012 5591 5594
19. M.O. Ota, A.A. Odutola, P.K. Owiafe, S. Donkor, and O.A. Owolabi Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants Sci Transl Med 3 2011 88ra56
20. J.D. Aronson, and C.E. Palmer Experience with BCB vaccine in the control of tuberculosis among North American Indians Public Health Rep 61 1946 802 820
21. S.R. Rosenthal, Loewinsohne, M.L. Graham, D. Liveright, and G. Thorne BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed Pediatrics 28 1961 622 641
22. M. Hatherill Prospects for elimination of childhood tuberculosis: the role of new vaccines Arch Dis Child 96 2011 851 856
23. H. Mulenga, S. Moyo, L. Workman, T. Hawkridge, and S. Verver Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials Vaccine 29 2011 4316 4321
24. M. Hatherill, S. Verver, H. Mahomed Taskforce on Clinical Research Issues STBPWGoTBV Consensus statement on diagnostic end points for infant tuberculosis vaccine trials Clin Infect Dis 54 2012 493 501
25. B.J. Marais, R.P. Gie, H.S. Schaaf, J.R. Starke, and A.C. Hesseling A proposed radiological classification of childhood intra-thoracic tuberculosis Pediatr Radiol 34 2004 886 894
26. A. Hawkridge, M. Hatherill, F. Little, M.A. Goetz, and L. Barker Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial BMJ 337 2008 a2052
27. R. English Boland/Overberg region health status report 2007/2008 2010 Department of Health
28. S. Moyo, S. Verver, A. Hawkridge, L. Geiter, and M. Hatherill Tuberculosis case finding for vaccine trials in young children in high-incidence settings: a randomised trial Int J Tuberc Lung Dis 16 2012 185 191
29. H. Geldenhuys, Z. Waggie, M. Jacks, M. Geldenhuys, and L. Traut Vaccine trials in the developing world: operational lessons learnt from a phase IV poliomyelitis vaccine trial in South Africa Vaccine 2012
30. D. Harrison, B. Stevens, M. Bueno, J. Yamada, and T. Adams-Webber Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review Arch Dis Child 95 2010 406 413
31. J. Willock, J. Richardson, A. Brazier, C. Powell, and E. Mitchell Peripheral venepuncture in infants and children Nurs Stand 18 2004 43 50 quiz 52, 55-46
32. M. Hatherill, M. Hanslo, T. Hawkridge, F. Little, and L. Workman Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa Bull World Health Organ 88 2010 312 320
33. H. Mahomed, and P.B. Fourie Clinical trials of TB vaccines: harmonization and cooperation Tuberculosis (Edinb) 92 Suppl. 1 2012 S21 S24
34. S.M. Graham, T. Ahmed, F. Amanullah, R. Browning, and V. Cardenas Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel J Infect Dis 205 Suppl. 2 2012 S199 S208
35. Department of Health Guidelines for good practice in the conduct of clinical trials with Human participants in South Africa 2006 Department of Health Pretoria, South Africa
36. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 1996. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1) Step 4 Version.
37. I.R. Lubega, M.G. Fowler, P.M. Musoke, A. Elbireer, and D. Bagenda Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants J Acquir Immune Defic Syndr 55 2011 58 64
38. A.M. Buchanan, F.J. Muro, J. Gratz, J.A. Crump, and A.M. Musyoka Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region Trop Med Int Health 2010
39. E.S. Lugada, J. Mermin, F. Kaharuza, E. Ulvestad, and W. Were Population-based hematologic and immunologic reference values for a healthy Ugandan population Clin Diagn Lab Immunol 11 2004 29 34
40. L. Quinto, J.J. Aponte, J. Sacarlal, M. Espasa, and P. Aide Haematological and biochemical indices in young African children: in search of reference intervals Trop Med Int Health 11 2006 1741 1748
41. S.B. Troy, A. Rowhani-Rahbar, L. Dyner, G. Musingwini, and A.K. Shetty Hematologic and immunologic parameters in Zimbabwean infants: a case for using local reference intervals to monitor toxicities in clinical trials J Trop Pediatr 58 2012 59 62